Skip to main content

FGFR4-CAR T Cells

FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma

  • RegistryNCT06865664
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRhabdomyosarcoma
  • SponsorNational Cancer Institute (NCI)
How FGFR4-CAR T Cells worksNCT068656641 min

What the film says

Read the transcript

Rhabdomyosarcoma is the most common soft tissue cancer in children. Low-risk disease is usually cured; when it comes back, fewer than one in five survive five years.

The idea: every rhabdomyosarcoma cell carries the same surface receptor, so aim engineered T cells at it.

That receptor is FGFR4. NCI researchers showed it sits on essentially all rhabdomyosarcomas and drives the most aggressive form, so it need not even be tested. A patient's T cells are collected, given a receptor for FGFR4, and returned in one infusion after four days of chemotherapy clears space.

A first dose-finding study, ages three to thirty-nine, after at least two prior treatments failed. Srivandana Akshintala leads it at the NIH Clinical Center. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT06865664

    Most common pediatric soft tissue sarcoma; recurrent 5-year survival 17%; FGFR4 universally expressed in RMS; PAX3-FOXO1 super-enhancer drives it in FP-RMS; FGFR4 confirmation not required; Apheresis; Flu days −5 to −2, Cy days −4 to −2; infusion day 0 (+1 more lines)

The drug

What is being tested.

Single intravenous (IV) infusion on Day 0

30 mg/m2 per day IV on days -5, -4, -3, -2

Background: * Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood with an annual incidence of 4.5 cases per 1 million children and is the third most prevalent extracranial solid tumor of childhood after neuroblastoma and Wilms tumor. * RMS is divided into two main subtypes, fusion negative (FN-RMS) driven by RAS pathway mutations, and fusion positive rhabdomyosarcoma (FP-RMS) driven by PAX3/PAX7-FOXO1 fusion genes.

The study

How the trial runs.

Background: Rhabdomyosarcoma (RMS) is a cancer of soft tissues. It is the most common soft tissue sarcoma seen in children. RMS cancer cells have a protein called FGFR4 on their surface. Researchers want to try a new kind of treatment for RMS: They will collect a person s own T cells, a type of immune cell; then they will change the T cells so they are better able to target the FGFR4 protein and attack RMS tumor cells.

The modified T cells are chimeric antigen receptor (CAR) T cells. The treatment in this study is called FGFR4-CAR T cells. Objective: To test FGFR4-CAR T cells in children and young adults with RMS. Eligibility: People aged 3 to 39 years with RMS. The RMS must have failed to respond or returned after at least 2 rounds of standard treatment. Design: Participants will be screened. They will have physical exam, imaging scans, blood tests, and tests of their heart.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Histologically confirmed rhabdomyosarcoma by the NCI Department of Pathology.
  • Note: Since FGFR4 expression is universal in rhabdomyosarcoma, confirmation of FGFR4 expression is not required.
  • Relapsed or refractory rhabdomyosarcoma after at least two (2) cancer treatment regimens i.e., participants should have relapsed or progressed after upfront therapy (that includes any systemic chemotherapy with or without local control) as well as at least one salvage therapy (which can be systemic therapy, radiation, or surgery).
  • No available alternative curative therapies per standard of care.
  • Participants must have measurable disease per RECIST 1.1 or non-measurable disease on imaging.
  • Age >= 3 and <= 39 years old.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.